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A cquired immune deficiency syndrome (AIDS) remains a major global public health challenge,  
especially in developing countries.  In 2018,  770,000 
people died from AIDS-related illnesses globally,  and 
opportunistic infections were the leading cause (Available 
at : http://www.unaids.org/en/resources/fact-sheet).  
Cryptococcal meningitis (CM) is one of the most prev-
alent and lethal opportunistic infectious diseases affecting 
HIV-positive patients,  and it causes 181,000 deaths per 
year worldwide,  accounting for 15% of AIDS-related 
deaths [1].
HIV-infected patients with cryptococcal meningitis 
(HIV/CM) require the simultaneous administration of 
antifungal and antiretroviral treatments.  There are 
advantages and disadvantages for both earlier and later 
initiations of antiretroviral therapy (ART) in HIV/CM 
patients.  If ART is initiated early in HIV/CM patients,  
the possibility of the development of immune reconsti-
tution inflammatory syndrome (IRIS) is enhanced,  as is 
the development of immunologically mediated com-
partmentalized neuroinflammation [2].  Conversely,  if 
there is a delay in the patient’s immune function resto-
ration as occurs when the initiation of ART is delayed,  
the patient’s CM may worsen,  and/or the development 
of other opportunistic infections may occur.
In 2014,  the Cryptococcal Optimal ART Timing 
(COAT) group conducted a trial to search for the opti-
mal timing for ART initiation,  and they concluded that 
deferring ART for 5 weeks after the diagnosis of CM was 
associated with the patients’ significantly improved sur-
vival compared to the initiation of ART at 1 to 2 weeks 
post-diagnosis [3].  A retrospective study also indicated 
that compared to deferred ART initiation (≥ 4 weeks 
after CM diagnosis),  early ART initiation (< 4 weeks 
after CM diagnosis) may increase all-cause mortality in 
patients [4].  However,  in the context of amphotericin 
induction,  it was found that ART initiation nearer to 
3 weeks rather than 6 weeks after starting antifungal 
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therapy may prevent some of the later HIV-related 
mortality while not substantially increasing the risk of 
IRIS [5].
The inconsistency of the above-described study 
results demonstrates that unambiguous,  robust,  evi-
dence-based guidelines regarding the timing of ART 
initiation for HIV/CM patients have not been defini-
tively extracted from these studies,  and the optimal 
timing for ART initiation in HIV/CM patients remains 
controversial.  We therefore propose the following mul-
ticenter,  prospective,  randomized,  controlled study to 
investigate the optimal timing for the initiation of ART 
in HIV/CM patients.
Study objectives. The study will compare the 
clinical efficacy and safety of early ART and deferred 
ART in HIV/CM patients.
Endpoints
Outcomes.
Primary outcome: The mortality rate and IRIS inci-
dence at week 48; these will be compared between the 
two arms of the study.
Secondary outcomes:
(1)  The changes in the patients’ CD4 +  T-cell counts 
from baseline to week 48; these will be com-
pared between the two study arms.
(2)  The proportion of patients with HIV viral loads 
below the detection limit at week 48; this will be 
compared between the two study arms.
(3)  The incidence of adverse events during the study 
period.  This will be compared between the two 
study arms.
Study endpoints.
(1)  Completion of the 48-week follow-up as per the 
study protocol.
(2) Discontinuation of ART during the study period.
(3) Death.
Study discontinuation criteria.
(1)  Serious or life-threatening patient safety issues 
occur during the course of the study.
(2)  The sponsor requests termination of the study.
(3)  The study ethics committee or administrative 
authority requests that the study be terminated.
Eligibility Criteria
Diagnostic criteria. Confirmations of HIV infec-
tion will be established by the positivity of HIV anti-
body testing based on the results of a western blot anal-
ysis and the positive detection of HIV RNA [6].  The 
diagnostic criteria of CM are as follows [7]:
(1)  Identification of Cryptococcus in cerebrospinal 
fluid (CSF) by India ink staining,  CSF crypto-
coccal antigen positivity,  or CSF Cryptococcus 
culture positivity.
(2)  CSF examination: intracranial hypertension,  
increased CSF protein content,  reduced sugar 
content,  mild or moderate leukocytosis in CSF.
(3)  Symptoms and signs: mainly low-grade fever,  
headache,  nausea,  vomiting,  altered mental 
state,  confusion,  irritability,  memory impair-
ment,  behavioral changes,  lethargy,  stiff neck,  
or visual disturbance.
Inclusion criteria. Patients meeting the following 
criteria will be included:
(1) ≥ 18 years old
(2) Confirmed diagnosis of HIV-1 infection
(3) Definitive diagnosis of CM
(4) ART-naïve
(5) Willing to provide informed consent
(6)  Patient conditions will not influence compliance 
to study protocols.
Exclusion criteria. Patients will be excluded from 
the study if they:
(1)  Are allergic or intolerant to therapeutic drugs used 
in this trial
(2)  Have hemoglobin (Hb) < 60 g/L,  white blood cell 
count (WBC) < 1.0 × 109/L,  neutrophil count (N) 
< 0.5 × 109/L,  platelet count (PLT) < 50 × 109/L,  
blood amylase (AMS) > 2 × ULN (upper limit of 
normal),  serum creatinine (Scr) > 1.5 × ULN,  
aspartate aminotransferase (AST)/alanine ami-
notransferase (ALT)/alkaline phosphatase (ALP) 
> 5 times the value of ULN,  total bilirubin (TB) 
> 2 × ULN,  serum creatine phosphokinase (CK) 
> 2 × ULN
(3)  Have unstable concomitant heart disease,  brain 
disease,  lung disease,  kidney disease,  cancer,  or 
psychosis that may compromise compliance to 
study protocols
(4) Are pregnant or breastfeeding
(5) Are intravenous drug users
(6) Are not of Chinese nationality.
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Study Design
This study will be an open-label,  multicenter,  pro-
spective,  randomized,  and controlled clinical trial.  One 
hundred eligible HIV/CM patients will be enrolled at 
the following 17 medical centers in China: Chongqing 
Public Health Medical Center,  Beijing You’an Hospital 
of Capital Medical University,  Harbin Medical University,  
the Second People’s Hospital of Tianjin,  the First Hospital 
of Changsha,  the Eighth People’s Hospital of Guangzhou,  
Liuzhou General Hospital,  the Third People’s Hospital 
of Guilin,  the Third People’s Hospital of Shenzhen,  
Guiyang Public Health Clinical Center,  Public Health 
Clinical Center of Chengdu,  Kunming Third People’s 
Hospital,  Yunnan Provincial Infectious Disease Hospital,  
the Fourth People’s Hospital of Nanning,  Guangxi 
Longtan Hospital,  the First Affiliated Hospital of Zhejiang 
University,  and Xixi Hospital of Hangzhou.
We will randomize our cohort of 100 HIV/CM 
patients into two arms: (a) an early ART group,  defined 
as receiving the initiation of ART at 2 to 5 weeks after 
the initiation of antifungal therapy,  and (b) a deferred 
ART group,  defined as undergoing the initiation of ART 
at over 5 weeks after antifungal therapy initiation.  The 
efficacy and safety of treatment in each group will be 
assessed by a comparison of the groups’ mortality rates 
and the incidence of IRIS between the 2 study arms.  
The flow diagram of the study is provided as Fig. 1.
Ethics approval and consent to participate. This 
study has been approved by The Ethics Committee of 
Chongqing Public Health Medical Center (2019-003-02-
KY) and has been registered as one of the 12 trials under 
a general project at clinicaltrials. gov.  The registration 
number of the general project is ChiCTR1900021195.  
The approval of the Ethics Committees from each par-
ticipating site will be secured before the initiation of 
patient recruitment.
We will share the results of this study through pub-
lished medical journal articles and conference presenta-
tions after the study’s completion.
Before randomization,  all patients will sign an 
informed consent form before their enrollment in the 
study.
Treatment Methods
Follow-up. The study time points of patient 
screening,  enrollment and follow-up and the assess-
ment items at each visit are shown in Table 1.
Intervention. All of the patients will receive con-
ventional drug treatments for both CM and HIV in 
accordance with the recommendations of the Chinese 
Guidelines for the Diagnosis and Treatment of HIV/AIDS 
(2018) [6].
Antifungal therapy
In light of local Chinese guidelines regarding the 
management of HIV/CM,  we will use amphotericin B 
deoxycholate combined with flucytosine in the induc-
tion phase of treatment.  Fluconazole or voriconazole 
may also be used as an alternative therapy at the induc-
tion phase.  The attending physician may adjust regi-
mens based on the patient’s clinical condition.
ART therapy
In accord with local guidelines,  the preferred anti- 
retroviral regimen of tenofovir disoproxil fumarate (TDF) 
(300 mg/d) + lamivudine (3TC) (300 mg/d) + efavirenz 
(EFV) (600 mg/d) will be used for the treatment of HIV 
infection,  while other regimens are optional.
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Comparison of primary and secondary outcomes at week 48
between the two study arms
Fig. 1　 Flow diagram for patient enrollment,  randomization,  and 
follow-up.
Statistical Considerations
Randomization. A specific random number 
sequence will be generated by Medical Research 
Platform (a website which can be available at http://www. 
51yyt.org/FrontPage/Index.aspx, Copyright © 2016-2020 
SJS TECH) for each patient with consent.  Those who 
are enrolled will be randomized into one of the two 
study arms at a 1 : 1 ratio.
Sample size. The sample size will be 50 per treat-
ment arm in order to provide at least 80% power and an 
overall two-side alpha level of 0.05.  The expected loss-
to-follow-up rate will be 15%.
Data collection and quality assurance. In order 
to ensure the highest standard of research,  the follow-
ing steps will be taken to maintain the integrity of the 
data collected.  All participating investigators for this 
study will be comprehensively trained based on a stan-
dard operating procedure (SOP) manual.
(1).  Data collection
All data will be recorded in case report forms (CRFs) 
and also immediately recorded into the investigation 
database by Medical Research Platform.  Significantly 
abnormal data and data that are outside clinical accept-
able ranges (e.g.,  laboratory items > 20% of the normal 
value) must be explained by the attending physician.  
Investigators must also record and explain the occur-
rence of adverse events and patient drop-outs.
(2).  Quality assurance
We envisage that a stable pool of study investigators 
will persist with this study during the trial period.  The 
investigators will record CRFs meticulously to ensure 
that the contents of the database are true and reliable.  
We will implement a two-stage quality control protocol 
for this study: each investigator will be responsible for 
the primary quality control,  and the Chongqing Public 
Health Medical Center will be responsible for the sec-
ondary quality control.  Quality control personnel at all 
levels will regularly supervise the access to research 
units in order to ensure that the contents of the research 
plan have been strictly abided by,  and that research data 
entries are valid and correct.  The data monitor will 
review CRFs,  check the inclusion and exclusion criteria 
for each patient,  and ensure that the information on the 
CRFs is in agreement with those in the source medical 
records.
(3).  Data retention
CRFs are considered to be original data,  and they 
will be stored for ≥ 5 years after the completion of this 
investigation.  Access to the research data will require 
written informed consent from the principal investigator.
Data analyses. Primary and secondary outcomes 
112 Xu et al. Acta Med.  Okayama　Vol.  75,  No.  1
Table 1　 Time points of the patient screening, enrollment,  and follow-up
Visit 1 Visit 2 Visit 3 Visit 4 Visit 5 Visit 6 Visit 7 Visit 8
























Signs & Symptoms × × × × × × ×
Hematological analysis × × × × × × ×
Clinical chemistry studies × × × × × × ×
Serum Amylase levels ×
Myocardial enzymes ×
Urinalysis ×
Urine pregnancy test ×
CD4+  counts × × × × × ×
Quantitative plasma HIV-RNA × × ×
Electrocardiogram (ECG) ×
Brain CT/MRI × ×
IRIS (yes or no) × × × × × ×
Concomitant medications × × × × × × × ×
Adverse events × × × × × × ×
analyses will be conducted for all of the randomized 
patients,  whether they complete the study protocol or 
not.  Both the intent-to-treat exposed (ITT-E) analysis 
set and the per-protocol (PP) analysis set will be used to 
assess the primary and secondary outcomes.  Patients 
who do not follow the treatment regimens will be 
excluded from the PP analysis set.  If any data are not 
recorded,  the last observation carried forward (LOCF) 
method will be used.  We will compare the mortality 
rate in the two groups using time-to-event methods 
with Cox proportional-hazards models,  and the cumu-
lative incidence function will be used to compare the 
incidence of adverse events and IRIS between the two 
groups [8].  The confidence interval will be established 
at 95%,  and the significance level will be set at 5%.
Discussion
Most of the clinical research regarding HIV/CM 
patients has been conducted in African cohorts in 
Africa.  It is not clear whether the results of those stud-
ies can be safely and faithfully extrapolated to Asian 
populations and specifically to Chinese populations.  
Our proposed study will be a randomized,  controlled,  
multicenter trial of the timing of ART initiation in 
Chinese patients with CM,  involving 17 hospitals in ten 
provinces in China; the results of our study will thereby 
be applicable and generalizable to the entire Chinese 
population,  and indeed to all Asian populations.
We expect that there will be challenges during the 
implementation of this study.  Our study has a follow-up 
period of 48 weeks,  and this lengthy period may well be 
overly onerous and exhausting for some enrolled patients.  
There may be costs related to presenting to a hospital 
for follow-up that may not be able to be met by some 
patients in the cohort.  We also acknowledge that it cannot 
be guaranteed that the therapeutic drugs and drug regi-
mens,  testing kits and laboratory reagents being used 
for diagnostic purposes in the 17 different hospitals in 
our study will originate from one specific company,  and 
although we will endeavor to mitigate this variable to 
the best of our ability,  we are unable to guarantee abso-
lute uniformity of therapeutic drugs and regimens,  lab-
oratory testing methods,  reagents and results.
To ensure the highest standards of quality of this trial 
we will: (1) comprehensively counsel the enrolled patients 
regarding the aims and objectives of the study so that 
each patient understands the value and importance of 
their role in the study; (2) provide a superior standard 
of consulting service excellence to participants during 
the study period and after the study; (3) strive to 
ensure diagnostic and therapeutic uniformity among the 
enrolled patients at the 17 hospitals during the course of 
the study.  With these steps,  we hope to conduct a 
high-quality clinical trial,  the results of which will ben-
efit Chinese patients as well as patients around the 
world.
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